Lorem ipsum dolor sit amet consectetur adipisicing elit.
I Consent
Disclaimer
This presentation is intended for educational and informational purposes only.
Though
the presentation has been prepared by taking care and placing reliance on substantiable sources,
Novartis
does not assume responsibility for any information not being accurate, complete OR for any change in the
information or data post preparation of the presentation.
Further, any independent content, views, thoughts and experiences of the presenter are personal to
him/her
and Novartis does not take any accountability or responsibility for the views and opinions expressed by
the
presenter. Such personal views, thoughts, content etc. do not necessarily reflect Novartis’ position,
policies or views and Novartis does not necessarily endorse, certify, or guarantee the accuracy,
completeness, or reliability of such independent information presented.
The presenter is solely responsible for obtaining the necessary permissions and licenses to use any
photos,
videos, or any other items added by him/her. Novartis does not assume any liability whatsoever, for the
content, views, guidance, as well as any infringement of intellectual property rights by the presenter.
Novartis does not recommend the use of its products in unapproved indications, dosage and recommends to
refer to complete prescribing information prior to using any of the Novartis products
OK
Welcome to the Knowledge Portal
Select an option for a tool box
LDL-Connect
Lp(a) Connect
LDL-ConnectLp(a) Connect
A practical approach to help your patients achieve
their LDL-C goal & reduce their CV risk
LDL-C & ASCVD
Early LDL-C lowering reduces ASCVD risk in India.
Guideline LDL-C targets
Latest guidelines: < 55 mg/dL LDL-C for very high-risk.
Recommended LLT Intensification
Early combination LLT helps achieve LDL-C goals.
Inclisiran: Overview
Inclisiran: siRNA therapy for sustained LDL-C reduction.
Inclisiran: Efficacy & safety
Inclisiran lowers LDL-C with favourable safety profile.
Real-world evidence
Reviews global and Indian real-world data demonstrating Inclisiran’s effectiveness, high
adherence, and consistent LDL-C goal achievement.
LDLc and Risk Video
Assess Risk easily by using our calculators to risk profile your patient.
Lp(a) & LDL-C
Lp(a) is much more atherogenic than LDL; raises CV risk even at low LDL-C.
Lp(a) testing Guidelines
Guidelines recommend at least one Lp(a) test for all adults and high-risk patients.
Significance of Lp(a) testing
Lp(a) testing identifies hidden CV risk
Lp(a) & CVD risk
Elevated Lp(a) independently increases risk of CVD, stroke, and mortality.
Understanding Lp(a) Structure & Pathophysiology
Lp(a) is genetically determined, pro-atherogenic, and varies by ethnicity.